Comparative Pharmacology
Head-to-head clinical analysis: ROBAXIN 750 versus TRANCOPAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ROBAXIN 750 versus TRANCOPAL.
ROBAXIN-750 vs TRANCOPAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methocarbamol, the active ingredient in Robaxin-750, is a centrally acting muscle relaxant. Its precise mechanism is not fully understood, but it is believed to cause general central nervous system depression, possibly through inhibition of polysynaptic reflexes at the spinal cord level.
Trancopal (chlormezanone) is a centrally acting muscle relaxant and anxiolytic. Its exact mechanism is not fully understood, but it is believed to act on the central nervous system by depressing polysynaptic reflexes and possibly through GABAergic modulation.
750 mg orally four times daily (total daily dose 3000 mg).
200-400 mg orally every 6 hours as needed for acute musculoskeletal pain; maximum 1.6 g per day.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours (methocarbamol); clinical context: short half-life necessitates frequent dosing (q6h) and may lead to fluctuating plasma levels.
Terminal elimination half-life: 20-30 hours in healthy adults. Prolonged in hepatic impairment (up to 60 hours).
Renal: 90-95% as metabolites (mainly conjugated), <1% unchanged; biliary/fecal: minor; <2% eliminated in feces.
Primarily renal: ~95% as metabolites (glucuronides, sulfate conjugates) with <1% unchanged. Fecal: <5%.
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant